Posts found in:
Grantees

Bcl-2 Family Proteins as Metabolic Targets in Leukemia It was established in the early 1900s that cancer cells have increased rates of glucose metabolism. While inhibition of this metabolic program in cancer cells may provide a novel avenue for future cancer treatment, a lack of understanding how metabolic stress can cause cell death has precluded […]

In Vivo Models for Design and Optimization of Targeted Nanocarriers (Protocells) for Leukemia Therapy

Cell Death Regulation by Pro-Apoptotic BOK in Multiple Myeloma Although the chemotherapeutic bortezomib has dramatically improved the survival of myeloma patients, nearly everyone develops resistance. We identified that a protein called BOK, which is frequently deleted in cancer, coordinates multiple ways cells die in response to bortezomib. We aim to identify therapeutic targets to re-activate […]

Targeting NOXA methylation to overcome Bortezomib resistance in MCL Mantle cell lymphoma is an aggressive type of non-Hodgkin’s lymphoma characterized by frequent relapses and usually fatal in the majority of patients. We are trying to understand precisely why patients do not respond to Bortezomib, a standard chemotherapy for this disease using cutting-edge next generation sequencing […]

Novel approaches to enhancing the therapeutic index of chimeric antigen receptor T cell therapy for acute myeloid leukemia The aim of this project is to develop a technology that will allow a powerful immune cell attack against leukemia without damaging normal bone marrow cells, thereby increasing the safety of cancer immunotherapy.

Molecular Therapy of CNS Lymphoma Dr. Rubenstein’s team is investigating new approaches in the use of Rituximab, a monoclonal antibody which is an important drug in the treatment of non-Hodgkin’s lymphoma. Rituximab is the first antibody to be approved in the treatment of cancer and is currently used in the vast majority of patients with […]

Investigating the collaboration between microRNAs and oncogenes in leukemia Understanding the mutations that cause leukemia is critical to our ability to design novel therapies. We propose to determine the capacity of two molecules, which are found mutated together in human AML patients, to collaborate during initial leukemic transformation and later during resistance to therapies.

Targeting NEDD8 protein conjugation: a novel therapeutic strategy for acute lymphoblastic leukemia (ALL). Acute lymphoblastic leukemia (ALL) is the main cause of cancer related death in children. We have access to a brand new drug that kills these leukemia cells very effectively in the laboratory. We want to study this drug in detail and test […]

Microenvironment and Flt3 Signaling in MLL Leukemia Dr. Mulloy’s lab has recently shown that human blood stem cells can be induced to make leukemia upon introduction of a leukemia oncogene into these cells. This is one of the first models that use human cells rather than mouse cells to produce leukemia. This is a significant […]

Nonablative Allogenic Blood Stem Cell Transplantation for Patients with Indolent Lymphoid Malignancies Chronic lymphocytic leukemia (CLL) is a relatively slowly progressing form of leukemia affecting specialized white blood cells known as lymphocytes. CLL mainly affects older people. One of the most effective treatments for some leukemias, including CLL, is the use of allogenic transplants, in […]

Systematic, High-Throughput Developmental Therapeutics in High-Risk ALL Tragically, many adult and pediatric leukemia patients still succumb to their disease despite intensive combination chemotherapy, stem cell transplantation and improved supportive care. Failure of current treatments to eradicate all traces of disease in leukemia patients ultimately leads to clinical relapse with drug-resistant leukemic cells. By using leukemic […]

Tumor Antigen Receptor Vaccines for Active Immunotherapy of T Cell Malignancies One of the most promising areas of cancer research is the use of immunotherapies-therapies that capitalize on the body’s own immune defenses. An important avenue of immunotherapy research is the use of vaccines to stimulate the immune system to mount its own attack against […]